Pfizer has acquired 50% stake in IGNITE Immunotherapy. Pursuant to the acquisition, Pfizer will hold 50% equity investment in IGNITE and be responsible for providing research and development funding for three years.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The acquisition will allow Pfizer to develop a new research programme to discover novel vaccinia viruses and also to expand its presence in the immuno-oncology field.

KDB Capital has acquired 6.7% stake in Anygen.

The acquirer is a financial services provider company, while the target is a peptide synthesis provider.

Image: Pfizer has acquired 50% stake in IGNITE Immunotherapy.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact